My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 168

    1.

    2'-Deoxycoformycin (pentostatin) for lymphoid malignancies. Rational development of an active new drug.

    O'Dwyer PJ, Wagner B, Leyland-Jones B, Wittes RE, Cheson BD, Hoth DF.

    Ann Intern Med. 1988 May;108(5):733-43. Review.PMID: 3282467 [PubMed - indexed for MEDLINE]Related articles

    2.

    Pentostatin (2'deoxycoformycin) for the treatment of lymphoid neoplasms.

    Ho AD, Thaler J, Willemze R, Lauria F, Derossi G, Kuse R, Stryckmans P, Blanc CM, Cataldo F, McVie G, et al.

    Bone Marrow Transplant. 1989 Jan;4 Suppl 1:60-2.PMID: 2653520 [PubMed - indexed for MEDLINE]Related articles

    3.

    Deoxycoformycin (pentostatin): clinical pharmacology, role in the chemotherapy of cancer, and use in other diseases.

    Spiers AS.

    Haematologia (Budap). 1996;27(2):55-84. Review.PMID: 14651224 [PubMed - indexed for MEDLINE]Related articles

    4.

    Deoxycoformycin in the treatment of leukemias and lymphomas.

    Smyth JF, Prentice HG, Proctor S, Hoffbrand AV.

    Ann N Y Acad Sci. 1985;451:123-8.PMID: 3878113 [PubMed - indexed for MEDLINE]Related articles

    5.

    Deoxycoformycin in therapy of refractory lymphoid neoplasms.

    Ho AD, Thaler J, Kuse R, Willemze R, Mandelli F, Lauria F, Zittoun R, Stryckmans P.

    Onkologie. 1988 Feb;11(1):35-7.PMID: 3283623 [PubMed - indexed for MEDLINE]Related articles

    6.

    The role of pentostatin (2'-deoxycoformycin, dCF) in the management of lymphoproliferative malignancies.

    Spiers AS.

    Blood Rev. 1987 Jun;1(2):106-10. Review.PMID: 3332090 [PubMed - indexed for MEDLINE]Related articles

    7.

    Membrane phenotype and response to deoxycoformycin in mature T cell malignancies.

    Dearden CE, Matutes E, Hoffbrand AV, Ganeshaguru K, Brozovic M, Williams HJ, Traub N, Mills M, Linch DC, Catovsky D.

    Br Med J (Clin Res Ed). 1987 Oct 10;295(6603):873-5.PMID: 2890401 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Effectiveness of pentostatin (2'-deoxycoformycin) in refractory lymphoid neoplasms.

    Spiers AS, Ruckdeschel JC, Horton J.

    Scand J Haematol. 1984 Feb;32(2):130-4.PMID: 6608139 [PubMed - indexed for MEDLINE]Related articles

    9.

    Treatment of cutaneous T cell lymphoma with 2'-deoxycoformycin (pentostatin).

    Dang-Vu AP, Olsen EA, Vollmer RT, Greenberg ML, Hershfield MS.

    J Am Acad Dermatol. 1988 Oct;19(4):692-8.PMID: 3263401 [PubMed - indexed for MEDLINE]Related articles

    10.

    An investigation of 2'-deoxycoformycin in the treatment of cutaneous T-cell lymphoma.

    Grever MR, Bisaccia E, Scarborough DA, Metz EN, Neidhart JA.

    Blood. 1983 Feb;61(2):279-82.PMID: 6600401 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    The biochemical and clinical consequences of 2'-deoxycoformycin in refractory lymphoproliferative malignancy.

    Grever MR, Siaw MF, Jacob WF, Neidhart JA, Miser JS, Coleman MS, Hutton JJ, Balcerzak SP.

    Blood. 1981 Mar;57(3):406-17.PMID: 6970050 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    The treatment of hairy cell leukemia (HCL) with pentostatin (2'-deoxycoformycin, dCF).

    Spiers AS, Parekh SJ.

    Bone Marrow Transplant. 1989 Jan;4 Suppl 1:173-5. No abstract available. PMID: 2653498 [PubMed - indexed for MEDLINE]Related articles

    13.

    Clinical pharmacology of deoxycoformycin.

    Major PP, Agarwal RP, Kufe DW.

    Blood. 1981 Jul;58(1):91-6.PMID: 6263381 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Clinical, pharmacologic, and immunologic effects of 2'-deoxycoformycin.

    Cummings FJ, Crabtree GW, Wiemann MC, Spremulli EN, Parks RE Jr, Calabresi P.

    Clin Pharmacol Ther. 1988 Nov;44(5):501-9.PMID: 3263248 [PubMed - indexed for MEDLINE]Related articles

    15.

    Current status of clinical trials of m-AMSA, dihydroxyanthracenedione, and deoxycoformycin.

    Macdonald JS, Marsoni S, Bruno S, Poster D.

    Recent Results Cancer Res. 1982;80:323-30.PMID: 6977170 [PubMed - indexed for MEDLINE]Related articles

    16.

    Low-dose deoxycoformycin in lymphoid malignancy.

    Grever MR, Leiby JM, Kraut EH, Wilson HE, Neidhart JA, Wall RL, Balcerzak SP.

    J Clin Oncol. 1985 Sep;3(9):1196-201.PMID: 2993534 [PubMed - indexed for MEDLINE]Related articles

    17.

    Conversion of a stem cell leukemia from a T-lymphoid to a myeloid phenotype induced by the adenosine deaminase inhibitor 2'-deoxycoformycin.

    Hershfield MS, Kurtzberg J, Harden E, Moore JO, Whang-Peng J, Haynes BF.

    Proc Natl Acad Sci U S A. 1984 Jan;81(1):253-7.PMID: 6607471 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Deoxycoformycin: an active new drug for indolent lymphomas and hairy cell leukemia.

    O'Dwyer PJ, Cheson BD, Leyland-Jones B, King SA, Hoth DF.

    Oncology (Williston Park). 1988 Jun;2(6):17-23, 26-7. Review.PMID: 3079330 [PubMed - indexed for MEDLINE]Related articles

    19.

    Enzymes of purine metabolism in lymphoid neoplasms, clinical relevance for treatment with enzyme inhibitors.

    Ho AD, Ganeshaguru K.

    Klin Wochenschr. 1988 Jun 1;66(11):467-74. Review.PMID: 2841534 [PubMed - indexed for MEDLINE]Related articles

    20.

    Pentostatin (Nipent) in T-cell malignancies. Leukemia Cooperative Group and the European Organization for Research and Treatment of Cancer.

    Ho AD, Suciu S, Stryckmans P, De Cataldo F, Willemze R, Thaler J, Peetermans M, Döhner H, Solbu G, Dardenne M, Zittoun R.

    Semin Oncol. 2000 Apr;27(2 Suppl 5):52-7.PMID: 10877053 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity